$FOLD multi-bagger with multi-bottom recovery. $7.
Post# of 109
Posted On: 05/18/2016 6:11:25 PM
$FOLD multi-bagger with multi-bottom recovery. $7.07
called 6/18/14 $2.97
Website
Shares Outstanding: 127.05M
Float: 100.15M
% Held by Insiders: 4.04%
% Held by Institutions: 97.60%
Shares Short (as of Apr 29, 2016): 22.29M
Short Ratio (as of Apr 29, 2016): 8.07
Short % of Float (as of Apr 29, 2016): 29.11%
Shares Short (prior month): 24.67M
Headlines
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
called 6/18/14 $2.97
Website
Shares Outstanding: 127.05M
Float: 100.15M
% Held by Insiders: 4.04%
% Held by Institutions: 97.60%
Shares Short (as of Apr 29, 2016): 22.29M
Short Ratio (as of Apr 29, 2016): 8.07
Short % of Float (as of Apr 29, 2016): 29.11%
Shares Short (prior month): 24.67M
Headlines
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
(0)
(0)Amicus Therapeutics Inc. (FOLD) Stock Research Links
Scroll down for more posts ▼